Orbital Therapeutics Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2022

Location

Cambridge MA US

Primary Industry

Biotechnology

About

Based in the US, and co-founded by Giuseppe Ciaramella (CEO), Kristina Burow, and Carol Suh, in 2022, Orbital Therapeutics is a biotechnology research company working on the enhancement of global health by unleashing the full potential of RNA-based medicines. In April 2023, Orbital Therapeutics raised USD 270 million in series A funding led by returning investor ARCH Venture Partners, with participation from other returning investors Andreessen Horowitz and Newpath Partners. New investors Abu Dhabi Growth Fund, Agent Capital, Alexandria Venture Investments, Casdin Capital, EXOR, Heritage Medical Systems, iGlobe Partners, Invus, Moore Strategic Ventures, Redmile Group, Rellim Capital Management, and other unspecified investors also participated in the round. The company is working on building a platform that integrates and applies established and emerging technologies across RNA delivery methods excluding RNAi therapeutics, data science, and automation to develop medicines focused in the areas of vaccines, immunomodulation, protein replacement, and regenerative medicine and hence treat human diseases.

Current Investors

ARCH Venture Partners, Andreessen Horowitz, Newpath Partners

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development

Website

www.orbitaltx.com

Company Stage

Series A

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.